Philips Expands Cardiovascular Ultrasound Leadership with Transcend Plus AI Platform
SHERIDAN, WYOMING – August 27, 2025 – Royal Philips has unveiled Transcend Plus, the next-generation upgrade to its EPIQ CVx and Affiniti CVx cardiovascular ultrasound platforms, featuring FDA-cleared artificial intelligence (AI) tools and imaging enhancements that promise to accelerate cardiac workflows and boost diagnostic precision across care settings.
Breakthrough Imaging Enhancements Backed by FDA Clearance
The Transcend Plus upgrade introduces sharper 2D and 3D image quality, now cleared under multiple new FDA 510(k) designations. By improving contrast, resolution, and diagnostic visibility, the system enables clinicians to identify cardiac abnormalities more reliably—even in patients with complex anatomies or technically challenging cases. A new 2D Auto EF Advanced feature expands AI capabilities for contrast imaging, essential in left ventricular function assessments.